智通财经APP讯，白云山(00874)发布公告，广州白云山医药集团股份有限公司(“公司”)子公司广州王老吉药业股份有限公司(“王老吉药业”)于近日召开克感利咽口服液治疗急性咽炎(外感风热证)的 III期临床试验启动会，该III期临床试验项目正式启动。
克感利咽口服液于1997年获得新药证书和生产批件，是王老吉药业独家品种，收载于《中华人民共和国药典》2025年版一部，具有疏风清热，解毒利咽作用，主要用于感冒属风热外侵，邪热内扰证者。王老吉药业于2024年2月获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意开展用于急性咽炎(外感风热证)的确证性临床试验(即Ⅲ期临床试验)。王老吉药业近期正式启动III期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.